Illustration: Sarah Grillo/Axios
TPG and General Atlantic are among the PE firms circling Clinical Ink, a clinical trial tech business owned by GI Partners, Axios Pro has learned.
The big picture: Private equity and strategic acquirers have been active consolidators of clinical trial technology.
